Shicun Huang
Yingqi Chen2†
Yeting Lu
Xiaowei Hu
Qi Fang- 1Department of Neurology, First Affiliated Hospital of Soochow University, Suzhou, China
- 2Department of Neurology, Suzhou Hospital of Traditional Chinese Medicine, Suzhou, China
Background: Previous studies suggest a link between diet-derived circulating antioxidants and epilepsy, but the causal relationship is unclear. This study aims to investigate the causal effect of these antioxidants on epilepsy.
Methods: To assess the causal link between dietary antioxidants and epilepsy risk, we conducted a two-sample Mendelian randomization (MR) analysis. This involved examining antioxidants such as zinc, selenium, α- and γ-tocopherol, vitamin A (retinol), vitamin C (ascorbate), and vitamin E (α-tocopherol). We utilized instrumental variables (IVs) which were genetic variations highly associated with these commonly used antioxidants. Exposure data were sourced from a comprehensive genome-wide association study (GWAS). We aggregated data from the International League Against Epilepsy (ILAE) Consortium sample, which included various types of epilepsy, as an outcome variable. Finally, we applied the inverse variance weighting method and conducted sensitivity analyses for further validation.
Results: Based on the primary MR estimates and subsequent sensitivity analyses, the inverse variance weighting (IVW) method revealed that a genetically predicted increase in zinc per standard deviation was positively associated with three types of epilepsy. This includes all types of epilepsy (OR = 1.06, 95% CI: 1.02–1.11, p = 0.008), generalized epilepsy (OR = 1.13, 95% CI: 1.01–1.25, p = 0.030), and focal epilepsy (documented hippocampal sclerosis) (OR = 1.01, 95% CI: 1.00–1.02, p = 0.025). However, there is no evidence indicating that other antioxidants obtained from the diet affect the increase of epilepsy either positively or negatively.
Conclusion: Our research indicates that the risk of developing epilepsy may be directly linked to the genetic prediction of zinc, whereas no such association was found for other antioxidants.
1 Introduction
Epilepsy is a brain disorder defined by at least two unprovoked seizures over 24 h apart, one unprovoked seizure with a high recurrence risk, or an epilepsy syndrome diagnosis; it is considered resolved in individuals who have been seizure-free for 10 years and off medication for the last 5 years (1). As the most widespread severe chronic neurological condition, epilepsy affects 70 million people worldwide and has significant cognitive, social, psychological, and economic impacts (2, 3). Despite the availability of many new ASDs, the outcomes for newly treated epilepsy and the likelihood of drug resistance remain largely unchanged from earlier studies (4). Therefore, further investigation into the underlying mechanisms is urgently needed to develop new therapeutic approaches. Clinical and experimental studies indicate that oxidative stress is both a cause and a consequence of epilepsy progression (5, 6). The onset of epilepsy is linked to oxidative stress and the overproduction of reactive oxygen species (ROS) (7–9). Epileptic seizures induce oxidative stress, leading to further neuronal damage and triggering a chain reaction of subsequent seizures (10), with both factors interacting and influencing each other. Unfortunately, there is currently no effective medication available to reduce neuronal death by modulating oxidative stress and thereby improve epilepsy.
Many compounds with antioxidant properties have been extensively researched for their antiepileptogenic therapeutic potential, given the role of antioxidant defense systems in neutralizing the increased generation of reactive oxygen species (ROS) during seizures (11–13). Antioxidants found in dietary supplements (14, 15), such as vitamins E and C, vitamin A, carotenoids, zinc and selenium, attract special attention due to their accessibility and ease of intake modification. However, the impact of these diet-derived circulating antioxidants on epilepsy remains controversial. While some reports suggest these antioxidants are safe and without adverse effects, others indicate potential impacts on the central nervous system and an increased risk of seizures associated with their use (14, 16–18). Despite the global popularity of dietary supplements, including among patients with epilepsy (ranging from 10 to 56%) (14, 15, 19–21), evidence supporting their beneficial effects in epilepsy remains lacking.
The existing results are generally inconsistent, leading to uncertainty about the association between diet-derived circulating antioxidants and the risk of epilepsy. Current studies are primarily in early research stages, such as animal experiments, and there is limited clinical evidence. To address these limitations and improve the study design, Mendelian randomization (MR) analysis was incorporated (22). Genetic variation was used as an instrumental variable (IV) to establish robust causal inferences regarding the relationship between levels of common diet-derived antioxidants and the occurrence of epilepsy. This methodology helps minimize biases from confounding factors and reverse causality. By using genetic variations as proxies for antioxidant levels, this approach may facilitate a deeper understanding of preventive strategies for epilepsy and related conditions.
2 Methods
2.1 Study design
Figure 1 provides a schematic overview of the current investigation. We first obtained relevant genetic variations from extensive genome-wide association studies (GWASs) for carotene, zinc, selenium, vitamin A (retinol), vitamin C (ascorbate), and vitamin E (α-tocopherol). Summary data related to epilepsy were taken from the GWAS Catalog. Using several sensitivity analyses and a two-sample MR study, we assessed the causal links between diet-derived antioxidants and epilepsy (23). The MR analysis relies on three key assumptions: (1) the genetic variants must be associated with the exposure, (2) the genetic variants must influence the outcome through the exposure, and (3) the genetic variants must be independent of all confounding factors. Each original study received informed consent and ethical approval, and all data used in this investigation are publicly available.
Figure 1. Overview of the study design (A), Study design. (B), Data Sources of Exposures, Outcomes, and MR analyses. SNPs for dietary antioxidants (vitamin A, vitamin C, vitamin E, carotene, zinc, and selenium) were identified as genetic instrumental variables. Summary statistics for epilepsy associations were obtained from GWAS Catalog. For each exposure, MR analyses (primary analysis using inverse-variance weighted (IVW), weighted median, MR-Egger regression, and sensitivity analyses using Cochrane’s test, Egger intercept, and leave-one-out test) were performed. GWAS, genome-wide association study; SNP, single-nucleotide polymorphism; MR, Mendelian randomization.
2.2 Selection of genetic instrumental variables
The present study considered seven primary dietary-derived antioxidants: vitamin A (retinol), vitamin C (ascorbate) (24), vitamin E (α-tocopherol) (24), vitamin E (γ-tocopherol) (24), carotene, zinc (25), and selenium (25). Based on extensive GWASs, single-nucleotide polymorphisms (SNPs) associated with these diet-derived antioxidants were identified as instrumental variables (IVs), using the following criteria: p < 5 × 10–6, linkage disequilibrium (LD) with r2 < 0.001, and LD distance >10,000 kb. An F-statistic exceeding 10 signified a robust association between the IVs and antioxidants, with the strength of this correlation evaluated between SNPs and diet-derived antioxidants. The specific SNPs linked to antioxidants are detailed in Supplementary Table S1.
2.3 Outcome data sets
Through a meta-analysis (N case = 15,212, N control = 29,677) conducted by the International League Against Epilepsy Consortium on Complex Epilepsies(ILAE) in 2018 (26), we obtained GWAS summary statistics for epilepsy. Seizures and epileptic disorders were diagnosed following the International League Against Epilepsy (ILAE)’s classification and nomenclature rules. Harmonization techniques were used to align SNP effect sizes and remove strand mismatches. Summary statistics are available in Table 1. To our knowledge, there was no sample overlap between the outcome and exposure GWASs.
Table 1. Characteristics of diet-derived antioxidants and epilepsy datasets.
2.4 Statistical analysis
2.4.1 Two-sample Mendelian randomization analysis
In the primary MR analysis, inverse-variance weighted (IVW) regression was utilized, assuming no flawed genetic instruments such as directional pleiotropy (27). A fixed-effect IVW meta-analysis of the Wald ratios was performed, calculating the gene-outcome (log odds ratio) divided by the gene-exposure correlations for each instrumental variable, to derive the mean impact estimate from each outcome database individually (28). The results are presented as odds ratios (ORs), indicating the impact of antioxidants on epilepsy risk, either based on standard deviation (for retinol, carotene, zinc, and selenium) or natural log-transformed levels (for ascorbate, α-tocopherol, and γ-tocopherol). These ORs evaluate the causal relationship between the exposure and the outcome, assuming the MR assumptions are met.
2.4.2 Sensitivity analysis
To assess heterogeneity and horizontal pleiotropy, this study used Egger regression intercepts (29) and Cochrane’s Q test (30) for sensitivity analysis. Cochrane’s Q test evaluated heterogeneity among instrumental factors, while potential horizontal pleiotropy was examined using MR-Egger intercept tests. Additionally, a leave-one-out test was conducted by iteratively removing each SNP and re-estimating the MR data. Considering consistency across all MR approaches, the IVW method was chosen as the primary estimate for causal effects based on these analyses.
The study and analysis were performed using R-version 4.3.2, utilizing the MR and “TwoSampleMR packages” (31, 32).
3 Results
3.1 Exposure and outcome
Table 1 displays the characteristics of participants in the epilepsy and antioxidants datasets. Specifics on SNPs linked to vitamin A (retinol), vitamin C (ascorbate), vitamin E (α-tocopherol), vitamin E (γ-tocopherol), carotene, zinc, and selenium are provided in Supplementary Table S1. A total of 59 SNPs were included as IVs for each of the seven antioxidants. The F-statistic for each genetic tool used in this investigation exceeded 10.
3.2 Main findings
Table 2 displays the results of the MR analysis investigating the impact of zinc on epilepsy. The findings suggest a causal relationship between genetically determined blood zinc levels and three distinct types of epilepsy. This association is observed across all epilepsy types (OR = 1.06, 95% CI: 1.02–1.11, p = 0.008), generalized epilepsy (OR = 1.13, 95% CI: 1.01–1.25, p = 0.030), and focal epilepsy (documented hippocampal sclerosis) (OR = 1.01, 95% CI: 1.00–1.02, p = 0.025). Elevated blood zinc levels are linked to an increased risk of these three seizure types. Subsequently, we investigated the association between each of the seven diet-related antioxidants and their respective links to epilepsy overall and its subtypes, including all types, generalized, and focal epilepsy (with documented hippocampal sclerosis), as depicted in Figures 2–4. Furthermore, we examined the relationship between vitamin A (retinol), vitamin C (ascorbic acid), vitamin E (α-tocopherol), vitamin E (γ-tocopherol), carotenoids, and selenium levels in relation to overall epilepsy and various subtypes, as indicated in Supplementary Tables S2–S7. However, we did not observe a significant association between these antioxidants and epilepsy. Little evidence was found to support causal effects of other diet-derived antioxidants on epilepsy.
Table 2. Two-sample Mendelian randomization estimations showing the effects of diet-derived antioxidants on the risk of epilepsy and the estimations of heterogeneity and horizontal pleiotropy for results.
Figure 2. The association between genetically determined diet-derived antioxidants and the risk of all types of epilepsy. Estimated ORs (odds ratio) for the effect of per unit increase in vitamin A (retinol), vitamin C (ascorbate), vitamin E (α-tocopherol), vitamin E (γ-tocopherol), carotene, zinc, and selenium on all types of epilepsy from an inverse-variance weighted (IVW) analysis. *p-value <0.05.
Figure 3. The association between genetically determined diet-derived antioxidants and the risk of generalized epilepsy. Estimated ORs (odds ratio) for the effect of per unit increase in vitamin A (retinol), vitamin C (ascorbate), vitamin E (α-tocopherol), vitamin E (γ-tocopherol), carotene, zinc, and selenium on generalized epilepsy from an inverse-variance weighted (IVW) analysis. *p-value <0.05.
Figure 4. The association between genetically determined diet-derived antioxidants and the risk of focal epilepsy (documented hippocampal sclerosis). Estimated ORs (odds ratio) for the effect of per unit increase in vitamin A (retinol), vitamin C (ascorbate), vitamin E (α-tocopherol), vitamin E (γ-tocopherol), carotene, zinc, and selenium on focal epilepsy (documented hippocampal sclerosis) from an inverse-variance weighted (IVW) analysis. *p-value <0.05.
3.3 Sensitivity analysis
Cochrane’s Q test revealed heterogeneity in vitamin A (retinol) across all types of epilepsy and focal epilepsy (refer to Supplementary Table S5). Significant heterogeneity was observed in vitamin C (ascorbate) for generalized epilepsy and Juvenile Myoclonic Epilepsy (JME) (p < 0.05 in IVW and MR-Egger regression) (refer to Supplementary Table S4). Vitamin E (α-tocopherol) exhibited significant heterogeneity across all types of epilepsy, generalized epilepsy, focal epilepsy, and focal epilepsy (documented lesion other than hippocampal sclerosis) (p < 0.05 in IVW and MR-Egger regression) (refer to Supplementary Table S2). Vitamin E (γ-tocopherol) showed heterogeneity in generalized epilepsy and Juvenile Absence Epilepsy (JAE) (refer to Supplementary Table S3). Selenium demonstrated heterogeneity in focal epilepsy (documented hippocampal sclerosis) (refer to Supplementary Table S7). Additionally, MR-Egger regression revealed no signs of directional pleiotropy for any outcomes. After excluding outliers, MR-Egger exhibited pleiotropic p-values >0.05 (refer to Supplementary Tables S2–S7).
4 Discussion
In our study, we conducted a two-sample MR analysis to investigate the relationship between diet-derived antioxidants and epilepsy occurrence. Our findings revealed a clear association between genetically increased levels of circulating zinc and epilepsy. However, we did not find significant correlations between epilepsy and genetically elevated levels of other common antioxidants, including circulating ascorbate, α-tocopherol, γ-tocopherol, carotene, retinol, and selenium.
Epilepsy, a neurological disorder characterized by a persistent tendency to experience seizures (33), can lead to neuronal death and promote further seizures (34–36). Processes involved in epileptogenesis include changes in neuroinflammation, synapses, neurotransmitters, receptors, oxidative stress, mitochondrial dysfunction, cytokine signaling, and apoptosis (37–39). Oxidative stress plays a crucial role in epilepsy development, with emerging research increasingly supporting a connection between epilepsy and heightened production of reactive oxygen species (ROS) production. Seizures can trigger the production of reactive oxygen/nitrogen species (ROS/RNS), leading to oxidative stress and cellular damage (40, 41). At the same time, the production of reactive substances or impaired activity of the antioxidant system underlies various forms of epilepsy, thus increasing the risk of recurrent seizures (42, 43). Both clinical and experimental studies suggest that oxidative stress plays a dual role as both a cause and consequence in the progression of epilepsy (5, 6). Elevated levels of oxidative stress biomarkers are associated with various models of epilepsy (44). Therefore, inhibiting the production of oxidative stress is expected to be a therapeutic window of opportunity for seizure prevention.
Numerous studies have explored the therapeutic potential of antioxidant compounds in managing epilepsy. Dietary interventions can modify underlying physiological processes and positively impact clinical outcomes. Historically, dietary modifications have been investigated as potential treatments for epilepsy. Research has identified several nutrients with anti-inflammatory or antioxidant properties, such as vitamin A, vitamin C, omega-3 fatty acids, polyphenols, and carotenoids (45–50). Vitamin E helps to remove ROS from the body and protects lipids and proteins from oxidative damage (51, 52). It has potential as a continuous adjuvant treatment for refractory epilepsy (53, 54). Antioxidant defense mechanisms also involve Zinc (Zn2+) (55) and Selenium (Se2+) (56). Unfortunately, only a few antioxidant-containing therapeutic interventions have been thoroughly studied as supplementary therapy for epilepsy patients, and these studies only partially succeeded in evaluating their prospective benefits. High-quality data from direct clinical research on the application of antioxidants in epileptic patients are scarce.
Our study found that higher blood zinc levels increased the risk of seizures in specific epilepsy subtypes, including all types of epilepsy, generalized epilepsy, and focal epilepsy (documented hippocampal sclerosis). Previous studies suggest that zinc exhibits a biphasic response in the central nervous system, with both neurotoxic and neuroprotective effects depending on its concentration (57, 58). In epilepsy, zinc shows both pro and anti-convulsant effects (58–60). For patients with these three seizure types, it is crucial to monitor and manage their blood zinc levels to reduce the risk of zinc-induced seizures. Maintaining zinc homeostasis appears to contribute to its anti-epileptic effect (61). Moderate zinc levels, when combined with traditional anti-epileptic drugs, acts synergistically (62). Thus, supplementing with moderate amounts of zinc to maintain balanced levels may be effective (61). However, standardized zinc supplement intake and optimal blood zinc concentrations have yet to be established. This will be a focus of our future research. Meanwhile, our findings suggest that most other diet-derived circulating antioxidants, including ascorbate, α-tocopherol, γ-tocopherol, carotene, retinol, and selenium, are unlikely to have a causal association with the risk of epilepsy.
4.1 Study strengths
Our study design effectively mitigated residual confounding, addressed issues of reverse causality, and strengthened causal inferences regarding the associations between exposure and epilepsy. Despite a limited number of robust genetic instruments, the study demonstrated a strong capacity for investigating causality due to the minimal overlap between exposure and outcome data. The current literature on the efficacy of diet-derived antioxidants in epilepsy treatment is notably limited. Our MR analysis elucidated the enduring impact of elevated levels of diet-derived antioxidants, accounting for long-term risks unaffected by dietary supplementation. Notably, MR, unlike randomized controlled trials (RCTs), does not require direct subject exposure to antioxidants, allowing it to be implemented at any time without extensive time and resource demands. This approach also mitigates the potential for subjecting individuals to unnecessary risks and harms (63).
4.2 Study limitations
First, Cochran’s Q values in the MR analysis indicated heterogeneity for some exposures. Second, due to the statistical limitations of the published data we used, we were unable to test for a nonlinear causal association between antioxidant levels and epilepsy. Third, although some findings did not show a causal association with epilepsy, we cannot entirely exclude the possibility that the effect size was too small for detection. Finally, we restricted our analysis to individuals of European ancestry only.
5 Conclusion
This study establishes a significant foundation for evaluating the correlation between dietary-derived circulating antioxidants and epilepsy. Our study revealed that higher blood zinc levels were associated with an increased risk of seizures in specific epilepsy subtypes. However, we found no evidence supporting the effects of dietary-derived vitamin A, vitamin C, vitamin E and selenium on epilepsy risk in the general population. Our future research will focus on further exploring the relationship between zinc levels and seizure risk in epilepsy.
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary material.
Ethics statement
Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent from the patients/participants or patients/participants’ legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.
Author contributions
SH: Conceptualization, Data curation, Formal analysis, Methodology, Resources, Software, Writing – original draft. YC: Data curation, Formal analysis, Resources, Software, Writing – original draft. YW: Data curation, Formal analysis, Project administration, Resources, Writing – original draft. SP: Data curation, Methodology, Resources, Software, Writing – original draft. YL: Data curation, Investigation, Methodology, Resources, Writing – original draft. WG: Project administration, Software, Supervision, Validation, Writing – original draft. XH: Funding acquisition, Project administration, Supervision, Validation, Writing – review & editing. QF: Funding acquisition, Methodology, Project administration, Validation, Visualization, Writing – review & editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was supported by the National Natural Science Foundation of China, Grant No. 82071300 and Scientific Research Project on Elderly Health of Jiangsu Provincial Healthcare Commission No. LKM2022019.
Acknowledgments
The authors sincerely thank the Physician Scientist Team for their enthusiastic and meticulous teaching and guidance on Mendelian randomization study.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2024.1422409/full#supplementary-material
References
1. Fisher, RS, Acevedo, C, Arzimanoglou, A, Bogacz, A, Cross, JH, Elger, CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. (2014) 55:475–82. doi: 10.1111/epi.12550
2. Sun, H, Li, X, Guo, Q, and Liu, S. Research progress on oxidative stress regulating different types of neuronal death caused by epileptic seizures. Neurol Sci. (2022) 43:6279–98. doi: 10.1007/s10072-022-06302-6
3. Hodges, SLL, and Lugo, JN. Therapeutic role of targeting mTOR signaling and neuroinflammation in epilepsy. Epilepsy Res. (2020) 161:106282. doi: 10.1016/j.eplepsyres.2020.106282
4. Chen, Z, Brodie, MJ, Liew, D, and Kwan, P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. (2018) 75:279–86. doi: 10.1001/jamaneurol.2017.3949
5. Liu, D-H, Agbo, E, Zhang, S-H, and Zhu, J-L. Anticonvulsant and neuroprotective effects of paeonol in epileptic rats. Neurochem Res. (2019) 44:2556–65. doi: 10.1007/s11064-019-02874-6
6. Kaproń, B, Czarnomysy, R, Wysokiński, M, Andrys, R, Musilek, K, Angeli, A, et al. 1,2,4-Triazole-based anticonvulsant agents with additional ROS scavenging activity are effective in a model of pharmacoresistant epilepsy. J Enzyme Inhib Med Chem. (2020) 35:993–1002. doi: 10.1080/14756366.2020.1748026
7. Huang, WY, Lin, S, Chen, HY, Chen, YP, Chen, TY, Hsu, KS, et al. NADPH oxidases as potential pharmacological targets against increased seizure susceptibility after systemic inflammation. J Neuroinflammation. (2018) 15:140. doi: 10.1186/s12974-018-1186-5
8. Alqarni, F, Eweis, HS, Ali, A, Alrafiah, A, Alsieni, M, Karim, S, et al. The effect of coenzyme Q10 on liver injury induced by valproic acid and its antiepileptic activity in rats. Biomedicines. (2022) 10:168. doi: 10.3390/biomedicines10010168
9. Roganovic, M, Pantovic, S, and Dizdarevic, S. Role of the oxidative stress in the pathogenesis of epilepsy. Neurol Sci Neurophysiol. (2019) 36:1–8. doi: 10.5152/nsn.2019.11632
10. Grewal, G, Kukal, S, Kanojia, N, Saso, L, Kukreti, S, and Kukreti, R. Effect of oxidative stress on ABC transporters: contribution to epilepsy pharmacoresistance. Molecules. (2017) 22:365. doi: 10.3390/molecules22030365
11. Devi, PUM, Manocha, A, and Vohora, D. Seizures, antiepileptics, antioxidants and oxidative stress: an insight for researchers. Expert Opin Pharmacother. (2008) 9:3169–77. doi: 10.1517/14656560802568230
12. Costello, DJD, and Delanty, N. Oxidative injury in epilepsy: potential for antioxidant therapy? Expert Rev Neurother. (2004) 4:541–53. doi: 10.1586/14737175.4.3.541
13. Rowles, JO, and Olsen, M. Perspectives on the development of antioxidant antiepileptogenic agents. Mini Rev Med Chem. (2012) 12:1015–27. doi: 10.2174/138955712802762266
14. Kaiboriboon, K, Guevara, M, and Alldredge, BK. Understanding herb and dietary supplement use in patients with epilepsy. Epilepsia. (2009) 50:1927–32. doi: 10.1111/j.1528-1167.2009.02090.x
15. Easterford, K, Clough, P, Comish, S, Lawton, L, and Duncan, S. The use of complementary medicines and alternative practitioners in a cohort of patients with epilepsy. Epilepsy Behav. (2005) 6:59–62. doi: 10.1016/j.yebeh.2004.10.007
16. Samuels, N, Finkelstein, Y, Singer, SR, and Oberbaum, M. Herbal medicine and epilepsy: proconvulsive effects and interactions with antiepileptic drugs. Epilepsia. (2007) 49:373–80. doi: 10.1111/j.1528-1167.2007.01379.x
17. Lee, SW, and Chung, SS. A review of the effects of vitamins and other dietary supplements on seizure activity. Epilepsy Behav. (2010) 18:139–50. doi: 10.1016/j.yebeh.2010.04.013
18. Haller, C, Meier, K, and Olson, K. Seizures reported in association with use of dietary supplements. Clin Toxicol. (2005) 43:23–30. doi: 10.1081/clt-44771
19. Eyal, S, Rasaby, S, and Ekstein, D. Concomitant therapy in people with epilepsy: potential drug–drug interactions and patient awareness. Epilepsy Behav. (2014) 31:369–76. doi: 10.1016/j.yebeh.2013.09.041
20. Peebles, CT, McAuley, JW, Roach, J, Moore, JL, and Reeves, AL. Alternative medicine use by patients with epilepsy. Epilepsy Behav. (2000) 1:74–7. doi: 10.1006/ebeh.2000.0031
21. Sirven, JID, Drazkowski, JF, Zimmerman, RS, Bortz, JJ, Shulman, DL, and Macleish, M. Complementary/alternative medicine for epilepsy in Arizona. Neurology. (2003) 61:576–7. doi: 10.1212/01.WNL.0000073541.08356.47
22. Bochud, M, and Rousson, V. Usefulness of Mendelian randomization in observational epidemiology. Int J Environ Res Public Health. (2010) 7:711–28. doi: 10.3390/ijerph7030711
23. Burgess, S, Scott, RA, Timpson, NJ, Davey Smith, G, and Thompson, SGEPIC-InterAct Consortium. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol. (2015) 30:543–52. doi: 10.1007/s10654-015-0011-z
24. Shin, SY, Fauman, EB, Petersen, AK, Krumsiek, J, Santos, R, Huang, J, et al. An atlas of genetic influences on human blood metabolites. Nat Genet. (2014) 46:543–50. doi: 10.1038/ng.2982
25. Evans, DM, Zhu, G, Dy, V, Heath, AC, Madden, PAF, Kemp, JP, et al. Genome-wide association study identifies loci affecting blood copper, selenium and zinc. Hum Mol Genet. (2013) 22:3998–4006. doi: 10.1093/hmg/ddt239
26. Abou-Khalil, B, Auce, P, Avbersek, A, Bahlo, M, Balding, DJ, Bast, T, et al. Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nat Commun. (2018) 9:5269. doi: 10.1038/s41467-018-07524-z
27. Burgess, S, Butterworth, A, and Thompson, SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. (2013) 37:658–65. doi: 10.1002/gepi.21758
28. Staley, JR, and Burgess, S. Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genet Epidemiol. (2017) 41:341–52. doi: 10.1002/gepi.22041
29. Bowden, J, Davey Smith, G, and Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. (2015) 44:512–25. doi: 10.1093/ije/dyv080
30. Greco, MF, Minelli, C, Sheehan, NA, and Thompson, JR. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med. (2015) 34:2926–40. doi: 10.1002/sim.6522
31. Hemani, G, Zheng, J, Elsworth, B, Wade, KH, Haberland, V, Baird, D, et al. The MR-base platform supports systematic causal inference across the human phenome. eLife. (2018) 7:e34408. doi: 10.7554/eLife.34408
32. Yavorska, OO, and Burgess, S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. (2017) 46:1734–9. doi: 10.1093/ije/dyx034
33. Fisher, RS, van Emde Boas, W, Blume, W, Elger, C, Genton, P, Lee, P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. (2005) 46:470–2. doi: 10.1111/j.0013-9580.2005.66104.x
34. Mao, XY, Zhou, HH, and Jin, WL. Redox-related neuronal death and crosstalk as drug targets: focus on epilepsy. Front Neurosci. (2019) 13:512. doi: 10.3389/fnins.2019.00512
35. Grosso, S, Longini, M, Rodriguez, A, Proietti, F, Piccini, B, Balestri, P, et al. Oxidative stress in children affected by epileptic encephalopathies. J Neurol Sci. (2011) 300:103–6. doi: 10.1016/j.jns.2010.09.017
36. Attia, GM, Elmansy, RA, and Elsaed, WM. Neuroprotective effect of nilotinib on pentylenetetrazol-induced epilepsy in adult rat hippocampus: involvement of oxidative stress, autophagy, inflammation, and apoptosis. Folia Neuropathol. (2019) 57:146–60. doi: 10.5114/fn.2019.84423
37. He, LY, Hu, MB, Li, RL, Zhao, R, Fan, LH, He, L, et al. Natural medicines for the treatment of epilepsy: bioactive components, pharmacology and mechanism. Front Pharmacol. (2021) 12:604040. doi: 10.3389/fphar.2021.604040
38. Alyami, NM, Abdi, S, Alyami, HM, and Almeer, R. Proanthocyanidins alleviate pentylenetetrazole-induced epileptic seizures in mice via the antioxidant activity. Neurochem Res. (2022) 47:3012–23. doi: 10.1007/s11064-022-03647-4
39. Foiadelli, T, Santangelo, A, Costagliola, G, Costa, E, Scacciati, M, Riva, A, et al. Neuroinflammation and status epilepticus: a narrative review unraveling a complex interplay. Front Pediatr. (2023) 11:1251914. doi: 10.3389/fped.2023.1251914
40. Pisoschi, AM, and Pop, A. The role of antioxidants in the chemistry of oxidative stress: a review. Eur J Med Chem. (2015) 97:55–74. doi: 10.1016/j.ejmech.2015.04.040
41. da Fonsêca, DV, da Silva Maia Bezerra Filho, C, Lima, TC, de Almeida, RN, and de Sousa, DP. Anticonvulsant essential oils and their relationship with oxidative stress in epilepsy. Biomol Ther. (2019) 9:835. doi: 10.3390/biom9120835
42. Essig, CFF, and Flanary, HG. The importance of the convulsion in occurrence and rate of development of electrocon vulsive threshold elevation. Exp Neurol. (1966) 14:448–52. doi: 10.1016/0014-4886(66)90129-4
43. Martinc, BG, Grabnar, I, and Vovk, T. Antioxidants as a preventive treatment for epileptic process: a review of the current status. Curr Neuropharmacol. (2014) 12:527–50. doi: 10.2174/1570159X12666140923205715
44. Geronzi, U, Lotti, F, and Grosso, S. Oxidative stress in epilepsy. Expert Rev Neurother. (2018) 18:427–34. doi: 10.1080/14737175.2018.1465410
45. Rasmus, P, and Kozłowska, E. Antioxidant and anti-inflammatory effects of carotenoids in mood disorders: an overview. Antioxidants. (2023) 12:676. doi: 10.3390/antiox12030676
46. Tabassum, R, and Jeong, NY. Potential for therapeutic use of hydrogen sulfide in oxidative stress-induced neurodegenerative diseases. Int J Med Sci. (2019) 16:1386–96. doi: 10.7150/ijms.36516
47. Winiarska-Mieczan, A, Kwiecień, M, Jachimowicz-Rogowska, K, Donaldson, J, Tomaszewska, E, and Baranowska-Wójcik, E. Anti-inflammatory, antioxidant, and neuroprotective effects of polyphenols—polyphenols as an element of diet therapy in depressive disorders. Int J Mol Sci. (2023) 24:2258. doi: 10.3390/ijms24032258
48. Wu, Y, Zhang, J, Feng, X, and Jiao, W. Omega-3 polyunsaturated fatty acids alleviate early brain injury after traumatic brain injury by inhibiting neuroinflammation and necroptosis. Transl Neurosci. (2023) 14:20220277. doi: 10.1515/tnsci-2022-0277
49. Yang, M-T, Chou, IC, and Wang, H-S. Role of vitamins in epilepsy. Epilepsy Behav. (2023) 139:109062. doi: 10.1016/j.yebeh.2022.109062
50. Didier, AJ, Stiene, J, Fang, L, Watkins, D, Dworkin, LD, and Creeden, JF. Antioxidant and anti-tumor effects of dietary vitamins A, C, and E. Antioxidants. (2023) 12:632. doi: 10.3390/antiox12030632
51. Zakharova, I, Sokolova, T, Vlasova, Y, Bayunova, L, Rychkova, M, and Avrova, N. α-Tocopherol at nanomolar concentration protects cortical neurons against oxidative stress. Int J Mol Sci. (2017) 18:216. doi: 10.3390/ijms18010216
52. Simeone, KA, Matthews, SA, Samson, KK, and Simeone, TA. Targeting deficiencies in mitochondrial respiratory complex I and functional uncoupling exerts anti-seizure effects in a genetic model of temporal lobe epilepsy and in a model of acute temporal lobe seizures. Exp Neurol. (2014) 251:84–90. doi: 10.1016/j.expneurol.2013.11.005
53. Mehvari, J, Motlagh, FG, Najafi, M, Ghazvini, MRA, Naeini, AA, and Zare, M. Effects of vitamin E on seizure frequency, electroencephalogram findings, and oxidative stress status of refractory epileptic patients. Adv Biomed Res. (2016) 5:36. doi: 10.4103/2277-9175.178780
54. Upaganlawar, AB, Wankhede, NL, Kale, MB, Umare, MD, Sehgal, A, Singh, S, et al. Interweaving epilepsy and neurodegeneration: vitamin E as a treatment approach. Biomed Pharmacother. (2021) 143:112146. doi: 10.1016/j.biopha.2021.112146
55. Kürekçi, AE, Alpay, F, Tanindi, S, Gökçay, E, Ozcan, O, Akin, R, et al. Plasma trace element, plasma glutathione peroxidase, and superoxide dismutase levels in epileptic children receiving AEDs therapy. Epilepsia. (1995) 36:600–4. doi: 10.1111/j.1528-1157.1995.tb02574.x
56. Burk, RF, Lawrence, RA, and Lane, JM. Liver necrosis and lipid peroxidation in the rat as the result of paraquat and diquat administration. Effect of selenium deficiency. J Clin Invest. (1980) 65:1024–31. doi: 10.1172/JCI109754
57. Sande, R, Doshi, G, and Godad, A. Deciphering the role of metal and non-metals in the treatment of epilepsy. Neurochem Int. (2023) 167:105536. doi: 10.1016/j.neuint.2023.105536
58. Franco-Pons, N. Zinc-rich synaptic boutons in human temporal cortex biopsies. Neuroscience. (2000) 98:429–35. doi: 10.1016/S0306-4522(00)00153-6
59. Doboszewska, U, Młyniec, K, Wlaź, A, Poleszak, E, Nowak, G, and Wlaź, P. Zinc signaling and epilepsy. Pharmacol Ther. (2019) 193:156–77. doi: 10.1016/j.pharmthera.2018.08.013
60. Gower-Winter, SD, and Levenson, CW. Zinc in the central nervous system: from molecules to behavior. Biofactors. (2012) 38:186–93. doi: 10.1002/biof.1012
61. Liu, W, Xu, J, Zhang, L, Li, F, Zhang, L, Tai, Z, et al. Research progress on correlations between trace element levels and epilepsy. Front Cell Dev Biol. (2023) 11:1167626. doi: 10.3389/fcell.2023.1167626
62. Fukahori, M. Effects of dietary zinc status on seizure susceptibility and hippocampal zinc content in the El (epilepsy) mouse. Brain Res. (1990) 529:16–22. doi: 10.1016/0006-8993(90)90806-M
Keywords: diet-derived circulating antioxidants, zinc, epilepsy, Mendelian randomization, oxidative stress
Citation: Huang S, Chen Y, Wang Y, Pan S, Lu Y, Gao W, Hu X and Fang Q (2024) Diet-derived circulating antioxidants and risk of epilepsy: a Mendelian randomization study. Front. Neurol. 15:1422409. doi: 10.3389/fneur.2024.1422409
Edited by:
Francesca Felicia Operto, University of Salerno, ItalyReviewed by:
Carmen Rubio, Manuel Velasco Suárez National Institute of Neurology and Neurosurgery, MexicoAndrea Santangelo, University of Pisa, Italy
Copyright © 2024 Huang, Chen, Wang, Pan, Lu, Gao, Hu and Fang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Qi Fang, fangqi_008@126.com
†These authors share first authorship
‡These authors share last authorship